Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accounts Payables (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Accounts Payables for 11 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 347.22% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 347.22% increase, with the full-year FY2025 number at $1.3 million, up 347.22% from a year prior.
  • Accounts Payables was $1.3 million for Q4 2025 at Cartesian Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.2 million in Q4 2023 to a low of $154000.0 in Q2 2021.
  • A 5-year average of $1.1 million and a median of $555500.0 in 2021 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 971.91% in 2024; the steepest drop was 90.86% in 2024.
  • Cartesian Therapeutics' Accounts Payables stood at $224000.0 in 2021, then soared by 41.07% to $316000.0 in 2022, then skyrocketed by 896.84% to $3.2 million in 2023, then plummeted by 90.86% to $288000.0 in 2024, then skyrocketed by 347.22% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Accounts Payables are $1.3 million (Q4 2025), $2.2 million (Q3 2025), and $454000.0 (Q2 2025).